Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 13/20 | 0.43 |
| ▸ | CRH | P06850 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069631 | 0.81 | CRHR1 (0.47) | CRHR1CRH | |
| SCHEMBL6070464 | 0.78 | CRH (0.59) | CRHR1CRH | |
| SCHEMBL6070559 | 0.78 | CRHR1 (0.55) | CRHR1CRH | |
| SCHEMBL1944898 | 0.75 | CRHR1 (0.47) | CRHR1HSD11B1 | |
| SCHEMBL2256347 | 0.69 | CRHR1 (0.38) | CRHR1HSD11B1 | |
| SCHEMBL6070738 | 0.69 | CRHR1 (0.45) | CRHR1HSD11B1 | |
| SCHEMBL6069992 | 0.69 | CRH (0.53) | CRHR1CRH | |
| SCHEMBL1922564 | 0.65 | HSD11B1 (0.41) | CRHR1HSD11B1 | |
| SCHEMBL22686426 | 0.64 | PIK3CA (0.36) | — | |
| SCHEMBL5847576 | 0.64 | HSD11B1 (0.42) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026317-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| US-6960583-B2 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147338-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885CRH 3/4885HSD11B1 398/4885 |
| US-20040176376-A1 | Pyrazolotriazines as CRF antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885CRH 3/4885HSD11B1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.